Table 1.
Baseline characteristics of participants included in the study
| Measure | Treatment group (n = 25) | Control group (n = 25) | Total sample (n = 50) |
|---|---|---|---|
| Age M (SD) | 42.71 (12.49) | 43.41 (14.57) | 43.04 (13.37) |
| PSWQ | 61.88 (11.21) | 57.95 (10.29) | 60.00 (10.84) |
| GAD-Q-IV | 10.01 (2.20) | 9.92 (2.24) | 9.87 (2.19) |
| MADRS-S | 24.04 (7.46) | 20.77 (7.35) | 22.48 (7.51) |
| PSQI | 10.58 (3.92) | 9.73 (3.49) | 10.17 (3.70) |
| DERS | 101.67 (20.18) | 97.64 (20.33) | 99.74 (20.13) |
| MAAS | 2.98 (0.65) | 3.64 (0.79) | 3.29 (0.78) |
| Sex | % (n) | % (n) | % (n) |
| Female | 72 (18) | 68 (17) | 70 (35) |
| Male | 28 (7) | 32 (8) | 30 (15) |
| Medication | |||
| Yes | 32 (8) | 48 (12) | 40 (20) |
| No | 68 (17) | 52 (13) | 60 (30) |
| Psychotherapy | |||
| Yes | 32 (8) | 36 (9) | 34 (17) |
| No | 68 (17) | 64 (16) | 66 (33) |
Note. PSWQ = Penn State Worry Questionnaire; GAD-Q-IV = Dimensional scoring from the Generalized Anxiety Disorder Questionnaire; MADRS-S = Montgomery-Asberg Depression Rating Scale; PSQI = Pittsburgh Sleep Quality Index; DERS = Dysfunctional Emotional Regulation Scale – Total mean score; MAAS: Mindful Attention and Awareness Scale; Medication: intends regular use of anxiolytic and antidepressant drugs (yes/no); Psychotherapy: intends ongoing treatment with psychotherapist (yes/no)